Mackenzie Financial
RETA

Mackenzie Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Mackenzie Financial’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,350
Closed -$693K – 1125
2019
Q2 		$693K Buy
+7,350
New +$635K ﹤0.01% 811

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mackenzie Financial's RETA Position: Q3 2019 in Review

Mackenzie Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2019, closing a stake of 7,350 shares — an estimated $693K sold.

Mackenzie Financial first reported a position in RETA in Q2 2019 and held it in 1 quarter. The position peaked at $693K in Q2 2019. 164 funds tracked by Wall St. Rank hold RETA as of Q3 2019.

  • Mackenzie Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2019 after selling out during the quarter.
  • Mackenzie Financial sold 7,350 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2019, an estimated $693K.
  • Mackenzie Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 1 quarter.
  • Mackenzie Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $693K in Q2 2019.
  • 164 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2019.

Based on Mackenzie Financial's 13F filing for Q3 2019, filed 14 Nov 2019.